expression levels in primary tumors of patients with lymph node metastasis exceeded levels in those without metastasis (65 vs. 35%, p = 0.048), and MAC30 expression in poorly differentiated tumors was higher than in well-differentiated ones (90 vs. 39%, p = 0.005). Conclusion: Overexpression of MAC30 in the cytoplasm of OSCC may predict nodal metastasis and poor differentiation.
MAC30 mRNA has been expressed in a variety of normal tissues, especially in testicular and gastric tissue. mRNA levels of MAC30 are significantly increased in breast and colon cancers but decreased in pancreatic and renal cancers. MAC30 protein is expressed in various normal tissues, such as esophageal, gastric, pancreatic and colon tissue, mainly in the mucosal cells and acinar and islet cells of the pancreas. In line with MAC30 mRNA transcription, expression of MAC30 protein was significantly increased in esophageal, gastric and colon cancers, but weak or absent in pancreatic cancer cells of primary tumors and metastases [2] . Recently, our research group found that cytoplasmic MAC30 expression levels significantly increased from distant normal mucosa to primary tumor and metastatic tissue, and was positively correlated with infiltrative growth and phosphatase of regenerating liver (PRL) levels, and tended to be positively correlated with Ki-67. Cytoplasmic MAC30 expression in metastatic lymph nodes indicated poor survival [3, 4] , suggesting a role in tumor development, tumor progression, invasion and metastasis, and its usefulness as prognostic factor.
Studies have shown that several molecular factors are not only involved in oral squamous cell carcinoma (OSCC) development but also associated with treatment response of OSCC patients [5] [6] [7] [8] . The p33
ING1b protein, a TP53-linked tumor suppressor, is one of the ING1 gene products [9, 10] and was found to be related to melanoma, acute lymphoblastic leukemia, seminoma, papillary thyroid and breast carcinoma [10] [11] [12] , as well as to OSCC [13] [14] [15] . Our previous study indicated that it was related to OSCC metastases [16] .
Particularly interesting, new cysteine-histidine-rich protein (PINCH) is an adapter protein consisting primarily of five LIM domains, and the gene is located on chromosome 2q12.2. PINCH is up-regulated in the stroma of different tumors [17] [18] [19] [20] [21] [22] [23] . Furthermore, PINCH has been considered a prognostic factor in patients with colorectal cancer [17] , and has been related to lymph node metastasis in OSCCs [21] . These data indicate that PINCH plays an important role in tumor development, and predicts invasive and metastatic potential.
The present study aimed to determine MAC30 expression in OSCC compared to normal oral mucosa, and to analyze the relationship between MAC30 expression in OSCC and clinicopathological variables, including patient gender and age, tumor location and size, lymph node status, grade of differentiation and biological factors (PINCH and p33
ING1b
).
Patients and Methods

Patients
Formalin-fixed paraffin-embedded tissues were obtained from the Department of Pathology of the First Hospital of the Hebei Medical University, Shijiazhuang, China. There were 43 OSCCs, including 20 gingival, 13 tongue and 10 buccal carcinomas. None of the patients had received preoperative radiotherapy or chemotherapy. The patients' gender and age, tumor size and location, lymph node status and differentiation were obtained from surgical and/or pathological records at the Hospital. Mean age of the patients was 54 years (from 26 to 80 years). The submandible and neck lymph nodes were taken to determine metastasis. All patients included in this study have given consent for the material taken for scientific research. According to the WHO classification, differentiation was graded as well, moderate or poor and undifferentiated. Well and moderately differentiated tumors were grouped as good differentiation, and poorly differentiated and undifferentiated tumors as poor differentiation. There were 20 normal oral mucous samples from orthodontic surgical operations. The samples were free from pre-cancer and cancer histologically. All slides (normal and tumor specimens) were confirmed by two pathologists (Z.-L.Z and Y.-H.Y.).
Data on PINCH [21] and p33 ING1b [16] expression, determined by immunohistochemistry, were from our previous study carried out at our laboratory. Of 57 OSCCs stained for PINCH, 30 cases were matched with the present cases for MAC30 analysis, and of 49 OSCC specimens stained for p33 ING1b , 27 cases were matched with the present cases for MAC30 analysis; the remainder did not have enough tissue for sectioning for MAC30 immunostaining. PINCH and p33 ING1b expression was graded as negative (none or ! 5% of positive cells) or positive, based on the intensity of PINCH staining in stromal cells and p33 ING1b staining in the nucleus and cytoplasm of normal and tumor cells.
Immunohistochemical Staining and Evaluation
Immunohistochemical staining was performed according to our previously published protocol [24] . Sections (5 m) were incubated at 60 ° C overnight, deparaffinized in xylene and rehydrated with graded ethanol and distilled water. In order to expose masked epitopes, sections were boiled in 0.01 M citrate buffer (pH 9.0) in a high-pressure cooker for 2 min, and then kept at room temperature for 30 min. In order to block endogenous peroxidase activity, sections were incubated with 3% H 2 O 2 -methanol for 20 min and washed with phosphate-buffered saline (PBS, pH 7.4). Then the sections were further treated with protein block solution for 10 min in order to avoid non-specific binding of the antibody. After removing the blocking solution, the sections were incubated with a monoclonal antibody MAC30 1-19 [2] in 1: 5 dilution, and diluted in antibody diluent (DAKO) at 4 ° C overnight. Then a biotinylated anti-rabbit IgG antibody (Fuzhou Maixin Biology, Fuzhou, China) was added for 30 min followed by incubation of an avidin-biotin-peroxidase (Fuzhou Maixin Biology) complex for 30 min. The sections were rinsed in PBS between the incubation steps. The peroxidase reaction was developed using diaminobenzidine (Beijing Zhongshan Biology, Beijing, China) for 8 min. After counterstaining with hematoxylin, sections were dehydrated and mounted. Sections known to stain positively were included as negative and positive controls. For negative controls, sections incubated with PBS instead of the primary antibody stained negatively, whereas positive controls stained positively.
The slides were microscopically examined and scored independently by two investigators (Z.-L.Z, pathologist, and D.-W.W., stomatologist) without any clinical or pathological information. To avoid artifacts, the areas with poor morphology, margins of the sections and necrosis were not considered. In the present study, we examined the staining of epithelial cells, tumor cells and stroma of tumor. Intensity of cytoplasmic staining was graded as negative (no positive cells), weak, moderate and strong staining. Nuclear staining was graded as negative (5%), 5-50, 50-75 and 1 75%, regardless of the staining intensity. In cases with discrepant results, a consensus score was reached after re-examination.
Statistical Analysis
The 2 method was used to test the relationship of MAC30 expression in normal oral mucosa and OSCC, as well as the relationship between MAC30 expression and clinicopathological/biological variables. All p values cited were two sided and p values ! 0.05 were judged as statistically significant.
Results
MAC30 expression was examined in 20 normal mucosa and 43 OSCC samples. Cytoplasmic MAC30 expression in normal mucosa and primary tumors is depicted in figure 1 .
According to the similarities of clinicopathological features, OSCC cases showing negative and weak MAC30 immunostaining were grouped as the weak group, and cases showing moderate and strong MAC30 immunostaining were grouped as the strong group.
Strong cytoplasmic expression of MAC30 was observed in 20% (4/20) of normal mucosa specimens and 51% (22/43) of primary tumors. The rate of cytoplasmic MAC30 expression was significantly higher in primary tumors than in normal mucosa (p = 0.019). MAC30 expression was also higher in primary tumors of patients with lymph node metastasis compared to those without metastasis (65 vs. 35%, respectively; p = 0.048), and expression in tumors with poor differentiation exceeded that in tumors with good differentiation (90 vs. 39%, respectively; p = 0.005; table 1 ). MAC30 expression was not significantly correlated with gender, age, tumor location and tumor size (p 1 0.05; table 1 ).
We also examined the relationship between cytoplasmic expression of MAC30 and PINCH and p33
ING1b , which was studied in our previous paper on OSCCs. There was no relationship of MAC30 with PINCH and p33
ING1b (p 1 0.05, data not shown).
There was 1 tumor with weak nuclear staining and 2 tumors with weak stromal staining. 
Discussion
MAC30 was first described to be overexpressed in meningiomas, and altered expression was also found in other types of human tumors [1, 2, 25] . The MAC30 gene is expressed in a broad spectrum of normal tissues, such as the brain, lungs, heart, skeletal muscles, testes, ovaries and pregnant uterus [25] . MAC30 was expressed at moderate levels in normal pancreatic acinar cells and low levels in most pancreatic cancer cells. In contrast to pancreatic cancer, MAC30 expression was stronger in breast, stomach and colon cancers than in the corresponding normal tissues [3, 4, 25] , indicating that MAC30 plays an important role in various types of malignancies.
In the present study, immunostaining of cytoplasmic MAC30 expression significantly increased from normal mucosa to primary tumor (20 vs. 53%, respectively; p = 0.02), being in line with results observed in esophageal, gastric, breast, stomach and colorectal cancer (our previous study) [2, 3] . These findings further confirmed that MAC30 may play a role in the development of malignancies including OSCC, perhaps acting as an oncogene.
Our previous study in colorectal cancers showed that cytoplasmic MAC30 expression increased from distant normal mucosa to primary tumor and to metastasis, and that strong cytoplasmic expression of MAC30 was significantly increased in cases of lymph node metastasis compared with non-metastatic cases (65 vs. 35%, respectively; p = 0.048). Taken together, these findings suggest a role for MAC30 in promoting metastasis. MAC30 might be a new biomarker predicting lymph node metastasis of OSCC and can provide valuable information for surgical treatment, since lymph node metastasis to the neck affects future surgical treatment, i.e. whether or not to resect the neck lymph node. Thus, a predictor to identify patients with lymph node metastasis before operation is a main clinical objective. Positive staining of MAC30 in a preoperative primary tumor biopsy, especially in the sentinel lymph node of the neck, combined with the positive expression of other biomarkers, e.g. PINCH and P33
ING1b [16, 21] , which have also been related to lymph node metastasis of OSCC, tumor size and tumor location, might help to decide whether resection of the lymph node of the neck before the operation is required. It can also help clinicians to decide whether radiotherapy or chemotherapy is needed after the operation. Negative MAC30 staining in the primary tumor, especially in the sentinel lymph node, perhaps suggests improved survival. It is interesting to design a study to examine MAC30 expression in preoperative biopsy samples to determine whether MAC30 expression is related to lymph node metastasis to the neck, cancer recurrence and eventually patient outcome. Since some molecular factors, e.g. thymidylate synthase, cyclin-dependent kinases and GLUT family members, may be related to treatment response in headand-neck cancer patients [5] [6] [7] [8] , further study of MAC30 expression in differently treated OSCC patients may help to determine possible associations between MAC30 expression and chemo-and/or radiotherapeutic strategies.
In the present study, cytoplasmic MAC30 expression was significantly stronger in cases of poor differentiation than in good-differentiation cases (90 vs. 39%, respectively; p = 0.005), indicating an association between MAC30 and OSCC differentiation. MAC30 mRNA is expressed as a non-erythropoietic gene in the fetal but not in the adult liver, suggesting a possible role in liver growth and differentiation. We hypothesize that with OSCC progression, especially in poorly differentiated tissue, the MAC30 gene then began to assume the role played in the fetal liver and functioned as a regulation protein to guide the differentiation of OSCC cells, thus up-regulating cytoplasmic MAC30 expression especially in poorly differentiated tumors, resembling the early stage of the fetal liver. The fact that MAC30 is involved in differentiation rather than proliferation is also supported by various other observations. MAC30 mRNA expression is down-regulated in human fibroblasts in response to serum [26] , and MAC30 expression is down-regulated by c-jun N-terminal kinase antisense oligonucleotides (JNK2AS) in human PC3 prostate carcinoma cells, in conjunction with growth suppression and induction of apoptosis in these cells [27] .
Conclusion
In the present study, we found that MAC30 was related to the development, invasiveness and lymph node metastasis of OSCC. Overexpression of MAC30 in the cytoplasm of OSCC may predict nodal metastasis and poor differentiation.
